Midatech Pharma is a nanomedicine company focused on the development and commercialisation of multiple high-value, targeted therapies for major diseases with unmet therapeutic needs.
Two Mewburn Ellis patent attorney partners, Simon Kiddle and Chris Casley, have helped Midatech to construct a leading biological nanotechnology patent portfolio. The patented technology covers use of carbohydrate-covered gold nanoparticles in drug delivery systems with a focus on the key therapeutic areas of diabetes and cancers.
“The ability to engineer new nanopharmaceuticals based on this patent protected platform technology, developed by Midatech, will have inherent advantages over existing treatments for multiple therapeutic areas.” EU Horizon 2020
The origins of the technology lie in work carried out by researchers at Consejo Superior de Investigaciones Cientificas (CSIC). Mewburn Ellis worked with Midatech right from the start of the project and helped identify the possibilities for patent protection. Since then, Midatech’s patent portfolio has gone from strength to strength and now comprises 30 patent families covering all major markets.
Mewburn Ellis trade mark attorney, Edmund Harrison has also helped Midatech to build up a global trade mark portfolio to protect their company and product names.
The strength of Midatech’s IP portfolio has helped it secured multiple rounds of private investment. In November 2014, as consortium leader, Midatech was awarded a Horizon 2020 grant of €7.9m to fund the manufacturing scale-up of therapeutics based on their gold nanoparticle technology. In December 2014, the company floated on AIM for £32m following their acquisition of Q Chip Limited.
In 2014, Midatech acquired Q Chip along with their IP portfolio directed to sustained release technology. Mewburn Ellis was glad to be able to assist in this process by liaising with other professional advisors such as lawyers and accountant involved in the acquisition to provide specialist IP due diligence advice. This involved assessing the strength of Q Chip’s patent portfolio and considering IP ownership issues.